MolMed receives approval for Phase III leukaemia trial in Italy
The multicentre, randomized Phase III trial will assess the very positive outcome of Phase I/II trial TK007 that resulted in an exceptional improvement in survival of patients by
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.